Hemoglobin-beta contributes to breast cancer neoangiogenesis and metastasis by a tumor cell protective antioxidant mechanism (40, 41), but also becomes a dominant self-antigen target of CD8 T cells in tumor pericytes following IL12 immunotherapy (42). The gene discussed is CD8A; the disease is breast cancer.